Michael Rape

Michael Rape is a Partner at The Column Group, a prominent life sciences venture capital firm based in San Francisco, California. Since joining the firm in 2018, he has managed an active portfolio of more than 20 biotechnology companies and contributed to the successful $400 million fundraise for The Column Group V in 2023. His investment track record includes guiding therapeutics startups from early drug discovery through commercialization, highlighted by the 2021 initial public offering of Revolution Medicines. Prior to his current position, he held life sciences investing roles at Third Rock Ventures and Atlas Venture, bridging complex scientific breakthroughs with long-term commercial viability. Holding a doctorate in chemistry from UC Berkeley, Rape currently focuses his efforts on financing early-stage biotechnology enterprises that are developing novel therapeutics across oncology, immunology, and neuroscience.